The University of Southampton
University of Southampton Institutional Repository

Molecular remission and non-Hodgkin's lymphoma

Molecular remission and non-Hodgkin's lymphoma
Molecular remission and non-Hodgkin's lymphoma
Non-Hodgkin's lymphomas are highly sensitive to treatment and complete clinical responses are often achieved. However, disease recurrence is common and is caused by the persistence of malignant lymphoma cells at a level below the limits of detection by conventional assessment such as clinical examination, bone marrow morphology and CT scans. This minimal residual disease can be detected using molecular techniques such as the polymerase chain reaction (PCR), and treatments capable of eliminating minimal residual disease are described as producing molecular remission. Molecular assessment is now commonly used as a measure of outcome in clinical trials of novel therapies for the treatment of lymphoma. The evidence for using molecular remission as a surrogate marker of clinical response in this setting is reviewed and the significance of minimal residual disease in determining prognosis and planning treatment strategies is addressed.
non-hodgkin's lymphoma, follicular lymphoma, mantle-cell lymphoma, minimal residual disease, bcl-2, chromosomal translocation, polymerase chain reaction, immunoglobulin rearrangement
549-562
Darby, Angela J.
37bf05d2-0075-4a39-9825-988680e8dcab
Johnson, Peter W.M.
1a86c9a9-25b4-4529-9353-d14fd062d63b
Darby, Angela J.
37bf05d2-0075-4a39-9825-988680e8dcab
Johnson, Peter W.M.
1a86c9a9-25b4-4529-9353-d14fd062d63b

Darby, Angela J. and Johnson, Peter W.M. (2002) Molecular remission and non-Hodgkin's lymphoma. Best Practice & Research: Clinical Haematology, 15 (3), 549-562. (doi:10.1053/beha.2002.0216).

Record type: Article

Abstract

Non-Hodgkin's lymphomas are highly sensitive to treatment and complete clinical responses are often achieved. However, disease recurrence is common and is caused by the persistence of malignant lymphoma cells at a level below the limits of detection by conventional assessment such as clinical examination, bone marrow morphology and CT scans. This minimal residual disease can be detected using molecular techniques such as the polymerase chain reaction (PCR), and treatments capable of eliminating minimal residual disease are described as producing molecular remission. Molecular assessment is now commonly used as a measure of outcome in clinical trials of novel therapies for the treatment of lymphoma. The evidence for using molecular remission as a surrogate marker of clinical response in this setting is reviewed and the significance of minimal residual disease in determining prognosis and planning treatment strategies is addressed.

Full text not available from this repository.

More information

Published date: 2002
Keywords: non-hodgkin's lymphoma, follicular lymphoma, mantle-cell lymphoma, minimal residual disease, bcl-2, chromosomal translocation, polymerase chain reaction, immunoglobulin rearrangement

Identifiers

Local EPrints ID: 26273
URI: http://eprints.soton.ac.uk/id/eprint/26273
PURE UUID: 300e260f-398a-40f2-bc20-c1772abe79fb

Catalogue record

Date deposited: 21 Apr 2006
Last modified: 15 Jul 2019 19:14

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×